Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NUS with free AI briefings, catalyst countdowns, and dilution alerts.

NUS · Nu Skin Enterprises, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$166.6M Cash on Hand
CF+ Cash Runway
Follow NUS by email Get an email when NUS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NUS, unsubscribe in one click. Privacy

📣 What NUS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Dietary Supplement: LifePak Nano Skin Diseases N/A · NCT00541931 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NUS holds $166.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NUS files for a raise →

👥 Who Owns NUS

Insiders 5.4% Institutions (235 holders) 75.2% Public and other holders 19.4%
HolderTypeShares% of sharesAs of
American Century Investment Management, Institution (13G, 5%+) 2,691,940 5.53% 2026-09-30
Ryan S Napierski
President and CEO, Director
Insider 1,001,905 2.06% 2026-03-06
Chayce David Clark
EVP, COO and CLO
Insider 390,746 0.80% 2026-03-06
James D Thomas
Chief Financial Officer
Insider 267,102 0.55% 2026-03-06
Steven Keith Hatchett
Chief Product Officer
Insider 260,818 0.54% 2026-03-06
Justin S Keisel
EVP, President of Global Sales
Insider 160,170 0.33% 2026-03-06
Daniel W Campbell
Director
Insider 129,244 0.27% 2026-06-01
Pisano R. Thomas
Director
Insider 116,827 0.24% 2026-06-01
Edwina D Woodbury
Director
Insider 62,474 0.13% 2026-09-09
Mark A Zorko
Director
Insider 60,586 0.12% 2026-06-01
Emma S. Battle
Director
Insider 57,648 0.12% 2026-06-01
Laura Nathanson
Director
Insider 57,116 0.12% 2026-06-01

Share count 48,678,057 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NUS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NUS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.